IWMON (OndoRussell2000 Tokenized ETF) 24-hour volatility reaches 108.6%: price rebounds from $120 low to $250.27, influenced by exchange expansion
Bitget Pulse2026/03/18 20:09Volatility Summary
In the past 24 hours, the IWMON price hit a low of $120, with a high and current price of $250.27, resulting in a price range fluctuation of 108.6%. The 24-hour trading volume was approximately $886,000, with a circulating market cap of around $2.03 million. Low liquidity makes the asset prone to significant volatility.
Analysis of Causes of Abnormal Fluctuations
- On March 17, 2026, Bitget announced the expansion of its spot market, adding Ondo tokenized ETF products including IWMon, increasing the market exposure of index ETFs.
No official announcements, notable on-chain whale transactions, or abnormal Dex monitoring data have been observed during the past 24 hours.
Market View and Outlook
There is little discussion within the community or on X platform. According to CoinGecko, the overall 24-hour increase is 1.8%, and market sentiment is neutral with a cautious tone. RWA tokenized assets are receiving overall attention, but the low circulating supply (8.2k tokens) amplifies risks. It is advised to be cautious of pullbacks arising from insufficient liquidity.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: Geopolitical uncertainty keeps markets on edge
Goldman Sachs Initiates Tempus AI (TEM.US) with "Neutral" Rating: Diagnostic Business Awaiting Reimbursement Dividends, Data Contracts Enter "Verification Period"
Goldman Sachs has assigned a "Neutral" rating and a $75 price target to Tempus AI; xT and xF reimbursement bonuses are expected, but the sustainability of contracts and competitive advantages with major pharmaceutical companies still needs to be validated.
Inside Strategy’s latest purchase and how $10B in losses turned to $8B in profits!